These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22720659)

  • 1. Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs.
    Kane-Gill SL; Forsberg EA; Verrico MM; Handler SM
    Drug Saf; 2012 Aug; 35(8):645-53. PubMed ID: 22720659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inter-rater agreement between WHO- Uppsala Monitoring Centre system and Naranjo algorithm for causality assessment of adverse drug reactions.
    More SA; Atal S; Mishra PS
    J Pharmacol Toxicol Methods; 2024; 127():107514. PubMed ID: 38768933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different methods for causality assessment of adverse drug reactions.
    Behera SK; Das S; Xavier AS; Velupula S; Sandhiya S
    Int J Clin Pharm; 2018 Aug; 40(4):903-910. PubMed ID: 30051231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causality assessment of adverse drug reactions in neonates: a comparative study between Naranjo's algorithm and Du's tool.
    Leopoldino RWD; de Oliveira LVS; Fernandes FEM; de Lima Costa HTM; Vale LMP; Oliveira AG; Martins RR
    Int J Clin Pharm; 2023 Aug; 45(4):1007-1013. PubMed ID: 37212967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions.
    Belhekar MN; Taur SR; Munshi RP
    Indian J Pharmacol; 2014; 46(1):117-20. PubMed ID: 24550597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of three algorithms used to evaluate adverse drug reactions.
    Michel DJ; Knodel LC
    Am J Hosp Pharm; 1986 Jul; 43(7):1709-14. PubMed ID: 3752106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An algorithm to detect adverse drug reactions in the neonatal intensive care unit.
    Du W; Lehr VT; Lieh-Lai M; Koo W; Ward RM; Rieder MJ; Van Den Anker JN; Reeves JH; Mathew M; Lulic-Botica M; Aranda JV
    J Clin Pharmacol; 2013 Jan; 53(1):87-95. PubMed ID: 23400748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference.
    Théophile H; André M; Miremont-Salamé G; Arimone Y; Bégaud B
    Drug Saf; 2013 Oct; 36(10):1033-44. PubMed ID: 23828659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the positive predictive values of antidote signals to detect potential adverse drug reactions (ADRs) in the medical intensive care unit (ICU).
    Kane-Gill SL; Bellamy CJ; Verrico MM; Handler SM; Weber RJ
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1185-91. PubMed ID: 19728294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of reported adverse drug reactions in a Tertiary Care Hospital in South India: A retrospective cross-sectional study.
    Gupta SK; Kumar KD
    Int J Pharm Investig; 2017; 7(4):193-197. PubMed ID: 29692979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confidence and accuracy in identification of adverse drug reactions reported by outpatients.
    Kampichit S; Pratipanawatr T; Jarernsiripornkul N
    Int J Clin Pharm; 2018 Dec; 40(6):1559-1567. PubMed ID: 30367372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?
    Kane-Gill SL; Kirisci L; Pathak DS
    Ann Pharmacother; 2005 Nov; 39(11):1823-7. PubMed ID: 16204392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions.
    Shukla AK; Jhaj R; Misra S; Ahmed SN; Nanda M; Chaudhary D
    J Family Med Prim Care; 2021 Sep; 10(9):3303-3308. PubMed ID: 34760748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective pharmacovigilance study in the infectious diseases unit of a tertiary care hospital.
    Karaismailoglu B; Saltoglu N; Balkan II; Mete B; Tabak F; Ozturk R
    J Infect Dev Ctries; 2019 Jul; 13(7):649-655. PubMed ID: 32065823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.
    Oosterhuis I; Zweers P; Rümke H; Muller-Hansma A; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):544-550. PubMed ID: 30168222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study.
    Murayama H; Sakuma M; Takahashi Y; Morimoto T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Severe Adverse Drug Reactions at a Free-Standing Children's Hospital.
    Yu D; Sheets J; Suppes S; Goldman J
    J Clin Pharmacol; 2019 Dec; 59(12):1569-1572. PubMed ID: 31309572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients.
    Vázquez-Alvarez AO; Brennan-Bourdon LM; Rincón-Sánchez AR; Islas-Carbajal MC; Huerta-Olvera SG
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):79. PubMed ID: 29216902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agreement between a regional pharmacovigilance centre and an adjudication committee regarding adverse drug reactions on a cohort of hospitalised children.
    Pages N; Bounabi A; Boussaha I; Ndiaye M; Portefaix A; Simeon G; Guy C; Stagnara J; Paret N; Vial T; Eftekhari P; Floret D; Gajdos V; Langhendries JP; Bleyzac N; Alberti C; Jacqz-Aigrain E; Nguyen KA; Kassai B;
    Therapie; 2022; 77(4):397-404. PubMed ID: 34998623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.